Insulin-like growth factor binding protein4 (IGFBP4) is a 24-26-kD protein expressed by a variety of cell types in vivo and in vitro. Treatment of normal adult human fibroblasts with 10 nM insulin-like growth factor II (IGF-II) for 24 h resulted in an 85% decrease in endogenous IGFBP4, as assessed by Western ligand blot analysis of the conditioned medium. Incubation of human fibroblast-conditioned medium (HFCM) with IGF-II under cell-free conditions led to a similar loss of IGFBP4. This posttranslationally regulated decrease in IGFBP-4 appeared to be due to a protease in HFCM: (a) It could be prevented with specific protease inhibitors or incubation at 40C; (b) proteolysis of recombinant human (rh) IGFBP-4 required HFCM; (c) immunoblotting and radiolabeling confirmed cleavage of IGFBP4 into 18-and 14-kD IGFBP4 fragments. The protease was specific for IGFBP4, and was strictly dependent on IGFs for activation. IGF-II was the most effective of the natural and mutant IGFs tested, inducing complete hydrolysis of rhIGFBP4 at a molar ratio of 0.25:1 (IGF/IGFBP4). Simian virus 40-transformed adult human fibroblasts also expressed IGFBP4 and IGFBP4 protease, as well as an inhibitor of IGFBP4 proteolysis. In biological studies, intact rhIGFBP4 potently inhibited IGF-I-stimulated [3HIaminoisobutyric acid uptake, whereas proteolyzed rhIGFBP-4 had no inhibitory effect. In conclusion, these data provide evidence for a novel IGF-dependent IGFBP4-specific protease that modifies IGFBP4 structure and function, and indicate a preferential role for IGF-II in its activation. Posttranslational regulation of IGFBP4 may provide a means for cooperative control of local cell growth by IGF-I and IGF-II.
Introduction
In recent years, six distinct insulin-like growth factor binding proteins (IGFBPs)' have been identified and designated as IGFBP-I through IGFBP-6 (1) (2) (3) (4) (5) (6) (7) (8) . The importance of these IGFBPs lies in their potential to modify the diverse metabolic and mitogenic effects of insulin-like growth factor (IGF) I and 11 (9) . IGFBPs are present in serum and other biological fluids and are secreted by a variety ofcells in culture, suggesting critical modulation of local as well as systemic action of the IGFs ( 10, 11 ) . Therefore, knowledge of the regulation of the different IGFBPs is fundamental to our understanding of IGF responsiveness at the cellular level. At present, the factors affecting IGFBP bioavailability are not completely understood. IGFBP-1, IGFBP-2, and IGFBP-3 mRNA expression can be regulated by various hormones and growth factors (12) (13) (14) (15) (16) (17) . Additionally, IGFBP-1 and IGFBP-3 have been shown to undergo posttranslational modifications, such as phosphorylation and proteolytic processing, that result in altered bioactivity (18) (19) (20) (21) .
Little is known about the regulation of IGFBP-4. IGFBP-4 is a 24-26-kD protein, originally isolated from the conditioned medium ofhuman bone cells and rat serum (6, 7) . It is secreted by a number of different cell types in vitro and IGFBP-4 mRNA is expressed in a variety of tissues (6, 7, (22) (23) (24) (25) (26) (27) (28) (29) . Although its precise biological function is unknown, IGFBP-4 has been implicated as a potent inhibitor ofIGF action in bone and in other systems (8, 22, 26, (30) (31) (32) . Recently, we reported that, in contrast to an increase in IGFBP-3, treatment of normal human fibroblasts and human osteoblast-like cells with IGF-I or IGF-II led to a marked reduction in the levels of 24-kD IGFBP-4 detected in the cell-conditioned medium (25, 33) . An IGF-induced decrease in human fibroblast-derived IGFBP-4 was also described by Neely and Rosenfeld (34) and Clemmons et al. (27) . Data from these studies indicated that this effect did not require IGF binding to type I or type II IGF receptors present on the cells. Interestingly, simian virus 40 (SV40)-transformed human fibroblasts, SV40-transformed human osteoblasts, a human epidermal squamous cell carcinoma line, and various osteosarcoma cell lines secrete 24-kD IGFBP, the medium levels of which are not affected by treatment of cells with IGF-I or IGF-II (25, 33, 34) .
In this study, we examined the mechanism by which IGFs regulate IGFBP-4 in cultured human fibroblasts. We present evidence for an IGF-activated protease that is specific for IGFBP-4 and that modifies IGFBP-4 structure and function. Furthermore, our data suggest involvement of an inhibitor, dominant in the transformed fibroblasts, that blocks proteolysis of IGFBP-4.
Methods
Materials. Recombinant human IGF-I and IGF-II were purchased from Amgen Biologicals (Thousand Oaks, CA) and Bachem, Inc. Cascieri (Merck Sharp & Dohme, Rahway, NJ). Recombinant human (rh) IGFBP-4, rhIGFBP-5, and rhIGFBP-6 were produced in yeast and purified by IGF-I affinity chromatography and HPLC (8) . IGFBP-4 antiserum was generated against rhIGFBP-4 in rabbits by Babco (Berkeley, CA), and is highly specific for IGFBP-4 (35 Cell-conditioned medium. Human dermal fibroblasts from normal adult donors (GM03652B) and SV40-transformed human fibroblasts (GM00637E) were purchased from the Human Genetic Mutant Cell Repository (Camden, NJ). Fibroblasts were cultured in DME supplemented with 100 U/ml penicillin, 100 Ag/ml streptomycin, and 4 mM glutamine, and containing 10% supplemented calf serum (HyClone Laboratories, Logan, UT).
At confluency, fibroblasts were washed twice and preincubated in a 1:1 mixture by volume of Waymouth's medium to DME plus 0.1% BSA serum-free medium (SFM) for 24 h. The cells were then washed and the medium changed to SFM for 72 h. At the end ofthe incubation period, the cell-conditioned medium was centrifuged at 2,000 g, 4VC for 30 min and stored frozen at -70°C. Medium conditioned by normal human fibroblasts is referred to as HFCM; medium conditioned by SV40-transformed human fibroblasts is referred to as SV40-HFCM.
Cell-free incubation. 50 (23, 24) . Binding in buffer alone was subtracted from the total bound radioactivity to determine specific binding.
Aminoisobutyric acid (AIB) uptake.
[3H]AIB uptake was determined as described previously (33, 39, 40) . Confluent bovine fibroblasts (24 multiwells) were washed three times with HBSS containing 1.75 g/l NaHCO3, 20 (33) . Moreover, incubation of control HFCM with IGF-II for 24 h at 37°C without cells resulted in the specific loss of 24-and 28-kD IGFBP-4 ( Fig. 1 B) . During this cell-free incubation, there was no decrease in IGFBP-4 in the absence of IGF-II. Furthermore, IGF-II did not alter IGFBP-3 levels and had no effect on other IGFBPs in HFCM. In time-and temperature-dependence studies (n = 3), IGFBP-4 in HFCM was decreased 73-82% within 2 h and was undetectable by 6 h of 37°C cell-free incubation with IGF-II; no loss of IGFBP-4 occurred with IGF-II when incubations were carried out at 4°C (data not shown). Addition of insulin (100 nM), growth hormone (1 jIg/ml), epidermal growth factor ( 10 nM), dexamethasone ( 100 nM), /-estradiol (1 ,uM), or progesterone (1 ,uM) to cultured cells or to cell-free conditioned medium had no effect on IGFBP-4 levels (data not shown). IGF-II, IGF-I, and various structural analogues of IGF-I were compared in their ability to modulate IGFBP-4 levels. Cell-free HFCM was incubated with or without 10 nM of each peptide for 24 h at 37°C and the samples analyzed by Western ligand blot ( Effect ofprotease inhibitors on IGF regulation ofIGFBP-4. Results of the cell-free experiments described above suggested that human fibroblasts may secrete an IGFBP-4-specific protease that is dependent upon IGFs for activation. Therefore, we tested various protease inhibitors on their ability to prevent IGF-II-induced decreases in IGFBP-4 in cell-free HFCM. EDTA and 1,10 phenanthroline, agents that complex divalent cations, blocked IGF-induced decreases in IGFBP-4 (Table I) . At high concentrations, benzamidine was also effective in inhibiting IGFBP-4 proteolytic activity, but other serine protease inhibitors (aprotinin, antipain, phenylmethylsulfonyl fluoride, and soybean trypsin inhibitor) had little or no effect at the concentrations tested. Detection of IGFBP-4 fragments. We further investigated IGF-II regulation of IGFBP-4 using recombinant human IGFBP-4 (rhIGFBP-4). In initial experiments, rhIGFBP-4 (50 ng _ 40 nM) was incubated with or without IGF-II (10 nM) for 24 h at 37°C in the absence or presence of cell-free HFCM. As shown in the Western ligand blot ofFig. 3, 24-kD rhIGFBP-4 was stable during the 24 h incubation in SFM (lane a) or in HFCM (lanes c, e, and g). IGF-II had no effect on rhIGFBP-4 in the absence of HFCM, but decreased rhIGFBP-4 50%, 88%, and 97% when HFCM was present as 10%, 40%, and 80% (lanes d, f and h, respectively) of the total incubation volume.
Under these same conditions, IGF-II had no effect on IGFBP-1 (from HepG2 cells [1, 23] ), IGFBP-2 (from BRL3A2 cells [3, 23] ), rhIGFBP-3, rhIGFBP-5, or rhIGFBP-6 (data not shown). 2 The availability of rhIGFBP-4 and IGFBP-4 antiserum allowed us to assess the nature of IGF-II-regulated IGFBP-4 by Western immunoblotting (Fig. 4) . In samples electrophoresed under nonreducing conditions, a single immunoreactive band at 24 kD was detected in samples containing 100 ng (-80 nM) rhIGFBP-4 and HFCM but no IGF-II. Inclusion of 10 nM IGF-II resulted in the complete loss of immunoreactive 24-kD IGFBP-4 and the appearance of faint bands at 18 and 14 kD. (Fig. 6 ). In comparison, at a 0.25:1 molar ratio (IGF/rhIGFBP-4) IGF-II, IGF-I, and des( 1-3)IGF-I were capable of inducing marked proteolysis of rhIGFBP-4, decreasing rhIGFBP-4 levels 97%, 88%, and 74%, respectively (Table II) IGF regulation of IGFBP-4 in SV40-transformed human fibroblasts. SV40-transformed human fibroblasts also secrete 38 /42-kD IGFBP-3 and a 24-kD IGFBP. As shown in Fig. 7 A, treatment of these cell cultures with 10 nM IGF-II markedly increased IGFBP-3 (sixfold), but did not alter levels of 24-kD IGFBP, similar to our previous findings (33) . It was possible that these cells produce negligible amounts of IGF-dependent IGFBP-4 protease and/or a variant of IGFBP-4 that is resistant (A) to proteolysis. However, incubation of SV40-HFCM with IGF-II in a cell-free system resulted in a 98% decrease in 24-kD IGFBP by Western ligand blotting, similar to the IGF-induced decrease in IGFBP-4 in HFCM (Fig. 7 B) . This decrease was confirmed as a loss of immunoreactive 24-kD IGFBP-4 (data not shown). As with HFCM, control incubations of cell-free SV40-HFCM did not alter the IGFBP profile and IGF-II had no effect on IGFBP-3.
To test whether SV40-transformed human fibroblasts produce an inhibitor ofIGF-dependent IGFBP-4 proteolysis, combination experiments were performed with these cells and exogenous HFCM containing both IGFBP-4 and IGFBP-4 protease (Fig. 8) . In a cell-free system, 5 nM IGF-II decreased IGFBP-4 in HFCM to undetectable levels (Fig. 8 A) . The presence of SV40-transformed human fibroblasts blocked the ability of IGF-II to decrease IGFBP-4 in HFCM (Fig. 8 B) . However, if SV40-transformed human fibroblasts were treated with cycloheximide (10 ,ug/ml) to inhibit ongoing protein synthesis, then the IGF-induced decrease in HFCM IGFBP-4 occurred (Fig. 8  C) . Cycloheximide had no effect on IGFBP-4 levels when added directly to HFCM during cell-free incubation (data not shown). Similar results were obtained in repeat experiments as well as in experiments using SV40-transformed human fibroblasts with SV40-HFCM. In contrast, the presence of normal human fibroblasts did not block the ability of IGF-II to decrease IGFBP-4 in HFCM (data not shown). IGF-I, as described in Fig. 1 
Discussion
In this study, we present evidence that IGF regulation of IGFBP-4 in human fibroblasts occurs via activation of a specific IGFBP-4 protease. Furthermore, our biological studies suggest a novel mechanism by which IGF-II-induced IGFBP-4 proteolysis can promote cell responsiveness to IGF-I. Treatment of cells with IGF peptides had been reported by us and others to decrease medium levels of IGFBP-4 (25-29, 33, 34) . In the present study we were able to reproduce the IGF-dependent decrease in IGFBP-4 in a completely cell-free system, demonstrating that the IGF effect can be exerted independent of any changes in IGFBP-4 expression or secretion. Thus, the direct addition of IGF-II to cell-free HFCM and incubation for as little as 2 h at 37°C resulted in significant loss of detectable IGFBP-4, as assessed by Western ligand blot. Only IGF peptides were able to elicit this response; no other growth factors tested, including insulin, growth hormone, epidermal growth factor, or various steroid hormones, had any effect on IGFBP-4 levels.
Involvement of a protease in HFCM was indicated by several lines ofevidence. The IGF-dependent protease is specific for IGFBP-4. Cellfree incubation with or without IGF-II had no effect on other IGFBPs present in HFCM or on IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-5, and IGFBP-6 added to HFCM. Therefore, it is unlikely to be the same as the recently described cation-dependent IGFBP-3 protease ( 19, 20) or the cation-independent serine protease, plasmin, which has been implicated in the proteolysis of IGFBP-1 (21 ) . Although the protease in HFCM could be active against different IGFBP substrates under different conditions, it is more probable that the protease responsible for IGFBP-4 processing in this study is the newest member of a growing family of IGFBP-specific proteases. Its uniqueness may derive from its IGF activation, a feature not specifically identified with the other recognized IGFBP proteases.
Preliminary identification of an inhibitor involved in the posttranslational regulation of IGFBP-4 derived from observations that, unlike findings with normal human fibroblasts, IGF-II treatment of cultured SV40-transformed human fibroblasts did not bring about a reduction in medium levels of IGFBP-4 (33 and Fig. 7 A) . However, when the conditioned media from these transformed cell cultures were treated with IGF-II in a cell-free system, a marked decrease in IGFBP-4 levels occurred. These results indicated that an IGF-dependent IGFBP-4 protease is present in the conditioned medium from SV40-transformed human fibroblasts as well as a potent inhibitor of IGFBP-4 proteolysis. Effective restraint of IGFBP-4 proteolysis appeared to require the continued synthesis and/or secretion of inhibitor. This hypothesis was tested by incubating HFCM (source of IGFBP-4 and IGFBP-4 protease) with or without IGF-II in the presence of SV40-transformed human fibroblasts. As we showed, SV40-transformed human fibroblasts prevented the decrease in HFCM IGFBP-4 with the addition of IGF-II. However, treatment of SV40-transformed huPosttranslational Regulation ofInsulin-like Growth Factor Binding Protein-4 1135 man fibroblasts with cycloheximide, an inhibitor of protein synthesis, allowed the IGF-II-dependent decrease in IGFBP-4 to proceed. These results suggest that SV40-transformed human fibroblasts produce an inhibitory protein involved in the IGFBP-4 proteolytic reaction. However, other explanations cannot be discounted at this time, and, like the IGFBP-4 protease itself, the identity of this inhibitor(s) awaits more thorough characterization.
IGF-controlled proteolysis of IGFBP-4 may be involved in a wide variety ofbiological systems. By using cell-free assay, we could demonstrate IGFBP-4 protease activity in medium conditioned by normal and transformed adult human fibroblasts. Preliminary studies indicate the presence of a similar protease in fetal human, bovine, rat, and sheep fibroblasts as well as human decidual cells (45, 46 , and our unpublished data). We have previously reported that incubation of normal human osteoblast-like cells with IGF-I or IGF-II results in an 80% decrease in levels of 24-kD IGFBP in the medium (25) , and have confirmed these results under cell-free conditions (our submitted manuscript). In addition, IGF-induced decreases in 24-kD IGFBPs have been noted in cultures of human decidual cells, human breast carcinoma cells, and a rat neuroblastoma cell line (26, 28, 29, 41 ) . It may be that posttranslational regulation of IGFBP-4 is as important as IGFBP-4 expression in determining IGFBP-4 availability.
In biological studies using cultured bovine fibroblasts, IGFBP-4 blocked IGF-I-stimulated [ 3H I AIB uptake when present in 5-fold molar excess. IGFBP-4 had no significant effect on [3H]AIB uptake stimulated by des( l-3)IGF-I or insulin, peptides with little or no affinity for IGFBP-4. These findings are in agreement with reports that IGFBP-4 inhibits IGF action in vitro by sequestering the peptide and preventing receptor interaction (8, 26, 30, 32) . Our study further demonstrated that relatively low amounts of IGF-II (molar ratio 0. 1:1 [ IGF-II/IGFBP-4]) induced IGFBP-4 proteolysis with consequential loss ofIGFBP-4 inhibitory function. IGF-II was more effective than IGF-I in activating IGFBP-4 proteolysis whereas IGF-I is more potent than IGF-II in activating type I IGF receptor signaling (39, 40, 44) , suggesting a novel mechanism for concerted control of cell growth by IGF-I and IGF-II. Thus at low levels, IGF-II could facilitate the breakdown of IGF inhibitory proteins , thereby increasing the availability ofIGF-I for receptor interaction. In this way, stimulatory effects of IGF-II may reflect ability to regulate IGFBP-4, independent of IGF-II cross-reactivity with the type I IGF receptor. This mechanism could play a significant role in bone with its high concentration of IGF-II in bone matrix (47) , osteoblastic production of IGFBP-4 (7, 25) , and IGF-regulated IGFBP-4 protease activity (25 and unpublished results). On the other hand, if intact IGFBP-4 is an important inhibitor of IGF-I-stimulated growth, then cell types which secrete IGFBP-4 but block localized IGFBP-4 proteolysis (via inhibitors of proteolysis and/or decreased IGFBP-4 protease production) would be expected to have limited responsiveness to IGFs. However, if growth requirements for IGFs are reduced (e.g., with transformation), then the resulting effect could be inhibition of adjacent cell growth and facilitated invasion into surrounding normal tissue. Thus, constraints on IGFBP-4 proteolysis could provide the potential for preferential tumor growth. It may be significant that IGFBP-4 is secreted by a variety of transformed and malignant cells and elevated levels of IGFBP-4 are, in many cases, associated with a transformed phenotype (25, 29, 3 1-34) .
In conclusion, identification of IGFBP proteases, especially those regulated by IGF peptides, adds a whole new dimension of complexity to our understanding of IGF physiology. Further studies are needed to evaluate the significance of our findings with respect to normal and abnormal cell growth.
